Search
Hengrui Medicine Secures Approval for Four Drug Clinical Trials
1 week ago /
Read about 0 minute
Author：小编
Hengrui Medicine and its subsidiaries have received approval notices from the National Medical Products Administration for the clinical trials of SHR-8068 Injection, Adebelimab Injection, Bevacizumab Injection, and Apatinib Mesylate Tablets. The company is now poised to commence these trials. The drugs encompass anti-CTLA-4, anti-PD-L1, anti-VEGF monoclonal antibodies, and small molecule targeted therapies, with respective R&D investments of approximately RMB 214 million, RMB 887 million, RMB 345 million, and RMB 587 million. Nonetheless, these drugs must successfully navigate clinical trials, as well as regulatory review and approval processes, before they can be commercialized and sold on the market.
-
C114 Communication Network -
Communication Home
7 X 24 Track global technological trends
